Article ; Online: Inhibition of drug-metabolizing enzymes by Qingfei Paidu decoction: Implication of herb-drug interactions in COVID-19 pharmacotherapy.
2021 Volume 149, Page(s) 111998
Abstract: ... of Qingfei Paidu decoction (QPD, a Chinese medicine compound formula recommended for combating COVID-19 ... in China) against human drug-metabolizing enzymes and to assess the pharmacokinetic interactions in vivo ... negative effects on human health. To fight against COVID-19 in a more efficient way, drug-drug or drug-herb ...
| Abstract | Corona Virus Disease 2019 (COVID-19) has spread all over the world and brings significantly negative effects on human health. To fight against COVID-19 in a more efficient way, drug-drug or drug-herb combinations are frequently used in clinical settings. The concomitant use of multiple medications may trigger clinically relevant drug/herb-drug interactions. This study aims to assay the inhibitory potentials of Qingfei Paidu decoction (QPD, a Chinese medicine compound formula recommended for combating COVID-19 in China) against human drug-metabolizing enzymes and to assess the pharmacokinetic interactions in vivo. The results demonstrated that QPD dose-dependently inhibited CYPs1A, 2A6, 2C8, 2C9, 2C19, 2D6 and 2E1 but inhibited CYP3A in a time- and NADPH-dependent manner. In vivo test showed that QPD prolonged the half-life of lopinavir (a CYP3A substrate-drug) by 1.40-fold and increased the AUC of lopinavir by 2.04-fold, when QPD (6 g/kg) was co-administrated with lopinavir (160 mg/kg) to rats. Further investigation revealed that Fructus Aurantii Immaturus (Zhishi) in QPD caused significant loss of CYP3A activity in NADPH-generating system. Collectively, our findings revealed that QPD potently inactivated CYP3A and significantly modulated the pharmacokinetics of CYP3A substrate-drugs, which would be very helpful for the patients and clinicians to avoid potential drug-interaction risks in COVID-19 treatment. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Animals ; Area Under Curve ; China ; Cytochrome P-450 CYP3A/metabolism ; Drugs, Chinese Herbal/pharmacology ; Drugs, Chinese Herbal/therapeutic use ; Herb-Drug Interactions ; Lopinavir/pharmacokinetics ; Male ; Microsomes, Liver ; NADP/metabolism ; Phytotherapy ; Rats, Sprague-Dawley ; SARS-CoV-2 ; COVID-19 Drug Treatment ; Rats | |||||
| Chemical Substances | Drugs, Chinese Herbal ; fructus aurantii immaturus ; qingfei paidu decoction ; Lopinavir (2494G1JF75) ; NADP (53-59-8) ; Cytochrome P-450 CYP3A (EC 1.14.14.1) | |||||
| Language | English | |||||
| Publishing date | 2021-01-19 | |||||
| Publishing country | England | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 782617-5 | |||||
| ISSN | 1873-6351 ; 0278-6915 | |||||
| ISSN (online) | 1873-6351 | |||||
| ISSN | 0278-6915 | |||||
| DOI | 10.1016/j.fct.2021.111998 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 529: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.